GSK set for high investment
The direction of GlaxoSmithKline’s high investment is now focused on Pakistan, as stated by GSK’s Finance Director Consumer Healthcare Middle East region, Paul Marson, at the re-launch ceremony of Sensodyne toothpaste. GSK is looking towards aggressive investments in developing healthcare products in Pakistan. The company has announced the injection of Rs. 2 billion for the initial investment phase. GSK believes Pakistan is a lucrative investment destination and expects profitable revenues for the company through new expansion.
Sensodyne is a product for sensitive teeth, which now onwards will be marketed to consumers directly instead of being promoted with dentists only. It is GSK’s aim to generate employment opportunities for the local population through heavy investments